Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-08-26
2009-02-24
Andres, Janet L. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C549S511000
Reexamination Certificate
active
07495114
ABSTRACT:
Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent or excipient is also included. A method for inducing cell death in selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent is included as well.
REFERENCES:
patent: 5399726 (1995-03-01), Holton et al.
patent: 5416064 (1995-05-01), Chari
patent: 5475011 (1995-12-01), Ojima
patent: 5475092 (1995-12-01), Chari
patent: 5728725 (1998-03-01), Holton et al.
patent: 5811452 (1998-09-01), Ojima
patent: 5824701 (1998-10-01), Greenwald
patent: 6028205 (2000-02-01), Holton et al.
patent: 6175023 (2001-01-01), Liu
patent: 6339164 (2002-01-01), Holton et al.
patent: 6340701 (2002-01-01), Chari
patent: 6372738 (2002-04-01), Chari
patent: 6436931 (2002-08-01), Chari
patent: 6455575 (2002-09-01), Golik et al.
patent: 6596757 (2003-07-01), Chari et al.
patent: 6649777 (2003-11-01), Holton et al.
patent: 6727369 (2004-04-01), Holton et al.
patent: 6958212 (2005-10-01), Hubbell et al.
patent: 2002/0040155 (2002-04-01), Holton et al.
patent: 0624377 (1994-05-01), None
patent: 0617034 (1994-09-01), None
patent: 0 639 577 (1995-02-01), None
patent: 1 022 284 (2000-07-01), None
patent: 1033372 (2000-09-01), None
patent: WO 89/12624 (1989-12-01), None
patent: WO9417050 (1994-08-01), None
patent: WO 95/07900 (1995-03-01), None
patent: WO 96/11683 (1996-04-01), None
patent: WO 96/23779 (1996-08-01), None
patent: WO 97/44026 (1997-11-01), None
patent: WO 98/19705 (1998-05-01), None
patent: WO 98/52614 (1998-11-01), None
patent: WO 00/50059 (2000-08-01), None
patent: WO 01/38318 (2001-05-01), None
patent: WO 01/56564 (2001-08-01), None
patent: WO 01/57013 (2001-08-01), None
patent: WO 01/57028 (2001-08-01), None
patent: WO 01/57029 (2001-08-01), None
patent: WO 01/57030 (2001-08-01), None
patent: WO0157030 (2001-08-01), None
patent: WO 03/097625 (2003-11-01), None
Kingston et al , J. Med. Chem. vol. 41 No. 19 pp. 3715-3726, (1998).
Safavy et al,J. Med. Chem., 42:4919-4924 (1999).
American Chemical Society Division of Medicinal Chemistry, Abstracts, 218thACS National Meeting, New Orleans, LA, Aug. 22-26, 1999, A. Trainor, Program Chair.
Synthesis and Biological Activity of Advanced 2nd-Generation, Taxoids, Tao Wang et al, Dept. of Chem., State Univ. of NY, at Stony Brook, NY 11794-3400; Dept. of Exp. Therapeutics, Roswell Park Cancer Inst., Elm and Carlton Streets, Buffalo, NY 14263, pp. 1-12.
Ojima et al,J. Med. Chem., 40:267-278 (1997).
Ojima et al,Proc. Natl. Acad. Sci., USA, 96:4256-4261 (1999).
Michael L. Miller, et al. “Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies”,Bioorganic&Medicinal Chemistry Letters14 (2004) 4079-4082.
Erkan Baloglu, et al. “Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors”,Bioorganic&Medicinal Chemistry Letters14 (2004) 5885-5888.
Michael L. Miller, et al. “Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery”,J. Med. Chem., 2004, 47, 4802-4805.
Office Action dated Jun. 13, 2006.
Rodi, D. J. et al., “Identification of small molecule binding sites within proteins using phage display technology”, Database CA [online] XP002443942, 2001.
Shi, Bing-Xing et al., “Studies on the quantitative structure-activity relationships of paclitaxel analogs”, Database CA [online] XP002443943, 2000.
Guenard, Daniel et al., “Effects of the hydrophobicity of taxoids on their interaction with tubulin”, Database CA [online] XP002443944, 2000.
Gueritte-Voegelein, Francoise et al., “Relationships between the structure of taxol analogs and their antimitotic activity”, Database CA [online] XPOO2443945, 1991.
Lui, Yanbin et al., “A Systematic SAR study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach”, Combinatorial Chemistry and High Throughput Screening, 5(1), 39-48 CODEN:CCHSFU; ISSN: 1386-2073, Feb. 1, 2002.
Ojima, Iwao et al., “Tumor-Specific Novel Taxoid-Monoclonal Antibody Conjugates”, Journal of Medicinal Chemistry, vol. 45, No. 26, pp. 5620-5623, Nov. 20, 2002.
Baloglu Erkan
Chari Ravi V. J.
Miller Michael
Andres Janet L.
Covington Raymond
Immunogen Inc.
Sughrue & Mion, PLLC
LandOfFree
Cytotoxic agents containing novel potent taxanes and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic agents containing novel potent taxanes and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic agents containing novel potent taxanes and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4109759